HENDERSON, Nev. and SAN DIEGO, March 5, 2019 /PRNewswire/ -- Secura Bio, Inc. (www.securabio.com), an integrated biopharmaceutical company dedicated to the worldwide commercialization of significant oncology therapies, today announced the closing of Secura Bio's $145 million equity and debt financing with funds managed by Athyrium Capital Management, LP (www.athyrium.com), a leading healthcare focused investment firm.
Secura Bio was founded by a proven executive team that has collectively launched/relaunched over 20 significant therapeutic products. This team previously founded and managed numerous successful life science companies to acquisition or public offering including: Sequus (acquired by Alza/J&J); Praecis (acquired by GSK); Aclara (IPO); Gevo (IPO); Prometheus (acquired by Nestle Health Science); Agarigen (acquired by Intrexon); and Genoptix (acquired by NeoGenomics).
"We are pleased to be partnering with Athyrium and appreciate their history of impressive investment results in life sciences," said Joseph M. Limber, President and Chief Executive Officer of Secura Bio. "We believe Athyrium's profile matches our ambition to aggressively build a profitable company based on worldwide commercialization of meaningful oncology therapies."
"We are excited about working with the Secura Bio management team to identify and acquire multiple therapeutic assets to achieve rapid growth and profitability," said Jeffrey Ferrell, Managing Partner at Athyrium. "We believe Secura Bio is well positioned to rapidly achieve a significant position in oncology therapeutics and represents a compelling investment opportunity."
About Secura Bio, Inc.
Secura Bio is an integrated biopharmaceutical company dedicated to the worldwide commercialization of significant oncology therapies for physicians and their patients.
About Athyrium Capital Management
Athyrium is a specialized asset management company formed in 2008 to focus on investment opportunities in the global healthcare sector. Athyrium advises funds with over $3.7 billion in committed capital. The Athyrium team has substantial investment experience across a wide range of asset classes including public equity, private equity, fixed income, royalties, and other structured securities. Athyrium invests across all healthcare verticals including biopharma, medical devices and products, healthcare focused services, and healthcare information technology. The team partners with management teams to implement creative financing solutions to companies' capital needs.
Advertisement
Secura Bio was founded by a proven executive team that has collectively launched/relaunched over 20 significant therapeutic products. This team previously founded and managed numerous successful life science companies to acquisition or public offering including: Sequus (acquired by Alza/J&J); Praecis (acquired by GSK); Aclara (IPO); Gevo (IPO); Prometheus (acquired by Nestle Health Science); Agarigen (acquired by Intrexon); and Genoptix (acquired by NeoGenomics).
Advertisement
"We are pleased to be partnering with Athyrium and appreciate their history of impressive investment results in life sciences," said Joseph M. Limber, President and Chief Executive Officer of Secura Bio. "We believe Athyrium's profile matches our ambition to aggressively build a profitable company based on worldwide commercialization of meaningful oncology therapies."
"We are excited about working with the Secura Bio management team to identify and acquire multiple therapeutic assets to achieve rapid growth and profitability," said Jeffrey Ferrell, Managing Partner at Athyrium. "We believe Secura Bio is well positioned to rapidly achieve a significant position in oncology therapeutics and represents a compelling investment opportunity."
About Secura Bio, Inc.
Secura Bio is an integrated biopharmaceutical company dedicated to the worldwide commercialization of significant oncology therapies for physicians and their patients.
About Athyrium Capital Management
Athyrium is a specialized asset management company formed in 2008 to focus on investment opportunities in the global healthcare sector. Athyrium advises funds with over $3.7 billion in committed capital. The Athyrium team has substantial investment experience across a wide range of asset classes including public equity, private equity, fixed income, royalties, and other structured securities. Athyrium invests across all healthcare verticals including biopharma, medical devices and products, healthcare focused services, and healthcare information technology. The team partners with management teams to implement creative financing solutions to companies' capital needs.
View original content:http://www.prnewswire.com/news-releases/secura-bio-announces-145-million-financing-led-by-athyrium-capital-management-300806408.html
SOURCE Secura Bio, Inc.
